PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases

INTRODUCTION: Immune checkpoint inhibitor (ICI) monotherapy has limited efficacy in patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs). With the wide use of ICI-based combinations, the efficacy of different ICI combination strategies in patients with NSCLC and BMs needs to b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Chenglong, Zhou, Fei, Li, Xuefei, Zhao, Chao, Li, Wei, Li, Jiayu, Xiong, Anwen, Yu, Jia, Gao, Guanghui, Wang, Qi, Wu, Fengying, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751843/
https://www.ncbi.nlm.nih.gov/pubmed/33363383
http://dx.doi.org/10.2147/OTT.S286600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751843/
https://www.ncbi.nlm.nih.gov/pubmed/33363383
http://dx.doi.org/10.2147/OTT.S286600

Ejemplares similares